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Head and Neck Squamous Carcinoma (HNSCC) is one of the most common 
cancers worldwide. HNSCC affects regions of the upper aerodigestive tract such as the 
lip, tongue, nasopharynx, oropharynx, larynx, and hypopharynx. About 25% of all 
HNSCC cases and up to 65% of Oropharyngeal Carcinoma (OPC) cases are positive for 
HPV DNA. African American patients, especially males, present primarily with HPV-
negative HNSCC. HNSCC’s that are HPV-positive tend to be HPV-active at initial 
presentation: these cancers contain HPV DNA and express HPV RNA. However, 
recurring HPV-positive cancers of the head and neck are more often inactive: these 
tumors contain HPV DNA, but do not express viral mRNA.  Previous gene expression 
profiling results identify a gene expression signature of HPV-inactive tumors that is 
“intermediate” between HPV-active and HPV-negative cancers. This study focuses on 
the molecular characteristics of HPV-inactive tumors and the molecular mechanisms by 
which these tumors may lose E6 and E7 oncogene expression. E6 and E7 are viral 
oncogenes whose expression drives cells to proliferate indefinitely and lose sensitivity to 
senescence and growth arrest mechanisms (immortalization). Our hypothesis is that 
tumors that are HPV-inactive began as HPV-active lesions, where tumor cells lost 
expression of E6/E7 by either mutation or epigenetic mechanisms or both. In these 
tumors, the growth promoting effects of E6/E7 should be replaced by mutations of 





mechanisms by which HPV-transformed cells can escape the need for continuous E6/E7 
expression for proliferation. In order to explore our hypothesis, we have developed two 
specific aims: 1) to determine whether mutated H-Ras (H-RasV12) expression results in 
changes in E7 mRNA and Rb protein levels in HKc. Our results indicate that H-RasV12 
partially replaces E7 function. 2) To determine whether p53 knock-down by the means of 
an shRNA can be achieved in Human Keratinocyte lines transformed with HPV16 
(HKc/HPV16) and their respective HKc/DR cells lines, and to assess the effect of p53 
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1.1 Head and neck cell carcinoma 
 
Head and Neck Squamous Carcinoma (HNSCC) is the 6
th
 most common cancer 
worldwide. HNSCC begins in the squamous cells that line the moist surfaces inside the 
head and neck (1); it affects regions of the upper aerodigestive tract such as the lip, 
tongue, nasopharynx, oropharynx, larynx, and hypopharynx. Nearly 50,000 new cases of 
HNSCC are diagnosed in the United States every year, and there are around 10,000 
deaths annually; it accounts for ~4% of all malignancies worldwide and 5% mortality of 
all cancers (1).  
 
The important risk factors associated with HNSCC include tobacco use, alcohol 
use (1, 2), human papillomavirus infection (HPV) and Epstein-Barr virus (EBV) (3). The 
incidence of HPV-negative HNSCC, which is mostly associated with smoking and 
alcohol consumption, has decreased by about 50% in the last 30 years, while the 
incidence of HPV-associated HNSCC has increased by a concerning 225% (4,5). It was 
also shown that HPV-associated head and neck cancers had better prognosis and 














Figure 1.1. Head and neck cancer regions. The location of paranasal sinuses, 
nasal cavity, oral cavity, tongue, salivary glands, larynx and pharynx (including 






1.2 Human Papillomavirus (HPV) 
 
Papillomaviruses (PVs) are members of the Papillomaviridae family (8).  PVs 
have small circular double stranded DNA genomes of approximately 8000 base pairs and 
icosahedral capsids (9).  PVs have a unique characteristic of well-adapting biological 
behavior in a specific host, for example HPV virus follows the differentiation 
programming of its host keratinocytes (reference). PVs are in both humans and animals 
and can be transmitted only through close cutaneous contact with infected exfoliated skin 
cells or muco-mucosal contact (10). PV genomes encode five proteins and are divided 
into three main regions: 1) the noncoding upstream regulatory regions (URR) which 
regulates viral gene expression. 2) The early region (E1, E2, E4, E5, E6, and E7) is 
critical for virus replication, oncogenesis and survival; E1 and E2 influence the 
replication cycle and transcription while the E4 protein contributes to the genome 
amplification efficiency. E5, E6 and E7 proteins maintain a key role in cellular growth 
regulation. 3) The late region (structural L1 and L2) encodes viral capsid proteins. This 
late region contains the L1 opening reading frame (ORF) and also is the most conserved 
amongst all papilloma virus types (10).  
 
 
1.2.1 HPV infection 
 
Although HPV infections are mostly subclinical, some of those subclinical 
infections can become clinical and may develop into tumors (11). The process of HPV 




by expression of early response genes (E1, E2, E4, E5, E6 and E7). The expression of 
these genes allows viral genome replication. Replication then moves to the upper cell 
layer and starts to differentiate (11). The expression of late genes, L1 and L2, as well as 
E4, is followed. L1 and L2 encapsidate the viral genomes to form progeny virions in the 
nucleus. The shed virus can then initiate a new infection, which in turn can cause HPV 
lesions arisen from the proliferation of infected basal keratinocytes. In addition, Low-
grade intraepithelial lesions support productive viral replication (12).  
 
Human papillomavirus (HPV) is the most common sexually transmitted infection 
(15). When HPV infection persists, it can produce precancerous lesions that may develop 
into invasive cancers. HPV has been found to be associated with many types of cancer 
including: cervical, vulvar, vaginal, penile, anal, and oropharyngeal (back of the throat, 
including the base of the tongue and tonsils). Although there are over 200 types of HPV 
that have been identified only 40 types are oncogenic (13,16), HPV16 is one of the most 
causative agents leading to invasive cancers, it was also found be associated with 








Lehoux et al. 2009.  
Figure 1.2 Papilloma virus life cycle HPV virus infects the basal 
epithelial cells through small lesion in the tissue, at this point the virus 
has minimal DNA replication and viral gene expression in basal cells 
(maintenance replication). Viral gene expression begins in the suprabasal 
cells, which induces proliferation due to E6 and E7, this process is 
followed by viral genome amplification. Late genes expression at the 
upper layers of the infected epithelium and lastly, virus assembly occurs 






1.3 P53 and RB pathway in HPV16-mediated carcinogenesis  
 
Tp53 is tumor suppressor gene that plays an important role in cell cycle and 
apoptosis. It is also called the “guardian” of the genome. The p53 protein transactivates a 
number of proteins with functions in cell cycle arrest and apoptosis (17). On the other 
hand, the tumor suppressor protein retinoblastoma (pRb) controls the expression of genes 
involved in cell cycle progression (18). These two tumor suppressor genes were found to 
have strong association with various type of cancer including HNSCC.  
In the case of HPV16-mediated carcinogenesis, the tumors are driven by the E6 
and E7 viral oncoproteins (19, 20). E6 and E7 are viral oncogenes whose expression 
drives cells to proliferate indefinitely and lose sensitivity to senescence and growth arrest 
mechanisms (immortalization) (20, 21).  E6 binds and degrades the p53 protein (22, 25), 
causing the cells to continue proliferating even in the presence of stressors or DNA 
damage.  E7 disrupts the interaction between Rb and E2F and promotes the degradation 
of Rb.  E7-mediated degradation of Rb frees up E2F to stimulate DNA replication and 
eventually cell division (23, 24, 26). Therefore, HPV hijacks cell cycle regulatory 
pathways and allows cells with damaged DNA to continue to grow and replicate. 
Mutations of p53 and Rb pathways alone can increase replication potential and cause 
immortalization (28). A number of studies have shown that different cancers showed the 
presence of p53 mutations (69.8% of HNSCC) (29) however, in HPV-mediated cancers, 
p53 function is just deactivated by E6 and mutations of p53 are rare. p53 function can 
also be inactivated by other mechanisms such as overexpression or amplification of 
MDM2 and deletion of the p14
ARF
 gene (29), loss of p16
INK4A




cyclin D1 associated with reduced survival (29). pRb can also be inactivated through the 
inactivation of the tumor-suppressive CDKN2A gene (targeted earlier in the HNSCC 
carcinogenesis). pRb mutations, however, are not very common in HNSCC, with  about 
7-9% mutation and copy number losses in 20–30% of cases (32). Instead, the H-RAS 
gene is significantly mutated in head and neck squamous cell carcinomas (HNC) and is a 
putative oncogenic driver (34). Oncogenic Ras mutations cause the protein to be 
perpetually active in the GTP-bound state resulting in increased proliferation and survival 
signaling (34). When looking at all human cancers, KRas mutations (part of the Ras 
family) are the most common type of Ras mutation (34), HRas being the least common. 
In addition, Oncogenic HRas mutations have been specifically found on codons 12, 13, 
61. Conversely, in HNSCC, Ras mutations appear to be exclusively H-Ras mutations 
(35).  
 
1.4 Rationales and Hypothesis 
Previous studies indicated that African American (AA) patients develop HPV-
negative Head and Neck Squamous Carcinomas (HNSCCs) more frequently than do 
European American (EA) patients (36, 37). It was also found that HPV in AA HNSCC 
patients is most often inactive, meaning that the tumors are positive for viral genomic 
DNA, but they do not express transcripts encoding E6 and E7 oncoproteins (37). About 
25% of all HNSCC cases, and up to 65% of Oropharyngeal Carcinoma (OPC) cases are 
positive for HPV DNA. African American patients, especially males, present primarily 
with HPV-negative HNSCC, and we have found that those that are HPV-positive by 













Figure 1.3: Mechanisms of oncogene activation: point mutation the Ras story 
When Ras is mutated, Ras becomes “stuck” in the “on” (GTP-bound) position 




HNSCC’s that are HPV-positive tend to be HPV-active at initial presentation, 
whereas HPV-positive recurring cancers of the head and neck are more often inactive 
(36).  Previous gene expression profiling results identify a gene expression signature of 
HPV-inactive tumors that is an “intermediate” between HPV-active, positive for viral 
DNA and expressing E6 and E7 transcripts and HPV-negative cancers where viral DNA 
is not present nor express E6 and E7 (36,37). The gene oncology analysis below (a 
former graduate student project) clearly shows that HPV-inactive tumors lack the cell 
cycle/mitosis/proliferation signature typical of HPV-active tumors. HPV-inactive tumors 
share many but not all the features of HPV-negative tumors, lacking changes in a whole 
class of pathways including cell projections, leading edge, adherens junctions. This 
difference supports our statement that the signature of HPV-inactive tumors is 
intermediate between that of HPV-active and HPV-negative. 
Our hypothesis is that tumors that are HPV-inactive began as HPV-active lesions, 
where tumor cells lost expression of E6/E7 by either mutation or epigenetic mechanisms 
or both. In these tumors, the growth promoting effects of E6/E7 should be replaced by 
mutations of relevant key genes. For example, E6 function could be replaced by 
homozygous deletion or mutation of p53; E7 function could be replaced by active ras. 
This project aims at uncovering specific molecular mechanisms by which HPV-

















Figure 1.4. Results of gene 
ontology analysis of 
microarray results from HPV-
active, HPV-inactive and 
HPV-negative OPC from 
European American patients 
(due to the small numbers of 





Since HPV-inactive tumors were found to have very distinct gene expression 
signatures from those of HPV-positive and HPV-negative tumors, this project is 
exploring TP53 and H-Ras mutation profiles of HNSCC in HPV inactive patients in order 
to determine their clinical and genetic characteristics. Characterizing the molecular 
profile of HPV-positive inactive tumors can greatly improve our understanding of the 
growth and progression of HPV16-mediated HNSCCs.  
This study focuses on the molecular characteristics of HPV-inactive tumors and 
the molecular mechanisms by which these tumors may lose E6 and E7 oncogene 
expression (figure 4). We reason that in cancer cells, E6 function could be replaced by 
homozygous deletion or mutation of p53; and E7 function could be replaced by active 
ras. Part of our efforts will be to show that these changes often occur in cultured HPV16-
transformed cells, to provide proof of principle for this concept. We will also study 
HNSCC samples to determine whether mutations of p53 and/or Ras are more frequent in 
HPV-inactive tumors. These mutations are extremely rare in HPV active HNSCC. 
 
1.5 Aims 
Based on the above hypothesis, we have developed the 2 specific aims. First, to 
determine whether mutated H-Ras (H-RasV12) expression results in changes in E7 and 
Rb expression levels in different HKc/HPV16. Second, To determine whether p53 can be 
knock-down by the means of an shRNA out Human Keratinocyte lines transformed with 
HPV16 (HKc/HPV16) and HKc/DR lines. These studies are meant to provide 
justification for a comprehensive mutation analysis of HNSCC specimens that will allow 
us to determine which mutations are associated with the HPV-inactive group, in 








Figure1.5 Possible mechanisms for the acquisition of independence from 
E6/E7 by HNC cells.  
HPV + 
Tumors (Inactive) 
Express viral DNA however does not express 
viral transcript E6 & E7 
Degradation of p53 and 










of cellular proteins 




An increase in p53 takes 
place during cell damage in 
order to cause a decrease in 
proliferation and induce 
apoptosis. 
 
HPV infected cells 
continue to proliferate. 
Ras 
p53 
Possible mechanism #1: 
Mutated HARasV12 essentially 
takes the place of E7 in the cell 
cycle entry process. 
Normally… 
Possible Mechanism #2: 
Homozygous deletion and/or 
methylation of p53 “replace” 
E6 function. P53 deletion or 





1.6 Broader Impacts  
 
The discovery that HPV-inactive HNSCC arise as HPV-active lesions, if 
confirmed by in vitro and ex vivo studies, would show that HPV-inactive cancers 
constitute a molecular and pathogenetic group of their own, distinct not only from HPV-
active but also from HPV-negative tumors. If HPV-inactive cancers begin as HPV-active, 
these cancers may be amenable to prevention with the HPV vaccines. In addition, there is 
a large body of controversial literature about the possible role of HPV in other cancers, 
such as the breast, the esophagus and the lung (to name a few). Currently, HPV DNA 
found in these tumors is interpreted as a mere passenger without a role in the 
development of those cancers. However if HPV-transformed cells can be mutated in such 
a way as to become independent of E6/E7 in the head and neck, perhaps the same 
mechanisms may operate at other sites. Therefore, these findings would lead to a 
complete revision of the role of HPV (and the potential preventive value of HPV 







CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1 Cell culture  
The HKc/HPV16d-1 (Pirisi et al., 1987) transformed cell line was used 
throughout this project. Cells were taken out of the liquid nitrogen container and plated 
on 100-mm tissue culture plate with Keratinocyte Serum Free media (KSFM). The plate 
was placed in incubator (37 degrees Celsius). After plating, cells were fed the following 
day and wash every 48 hours until 80% confluence. Cells were again allowed to grow 
once more to 80% confluence before transfection, UV treatment or protein extraction.  
 
 
2.2 Foreskin processing  
 
 
Normal HKc cells were isolated from neonatal foreskins using the following 
protocol. Foreskins were rinsed under sterile conditions in a wash vial containing 
MCDB153-LB (home made medium) basal media. Excess connective tissue and fat were 
removed from the dermis using a scalpel. Foreskins were incubated overnight in 
incubator (37 degrees Celsius) dermis side down, in 10% dispase. The epidermis was 
separated from the dermis with a pair of forceps in a 100 mm Petri dish. The epidermis 
was then trypsonized , spun  down and plated in a 100 mm cell culture dish using in 5 ml 
of complete medium . Cells were collected by centrifugation in a clinical centrifuge, 
speed 3 for 1 minute and speed 2 for 4 minutes. Cells pellet was re-suspended and plated 




PBS and fed once more with 15 ml of CM then incubated in a humidified atmosphere of 
95%air/5%CO2. Cells were fed fresh CM every 48 hour until cells reached 80% 
confluence.  
In order to knock-down p53 and overexpress H-Ras in the HPV16-transformed 
cell lines the following procedures were performed: 
 
2.3 Transforming competent cells  
The following materials were prepared: Water bath was equilibrated to 42 degrees 
Celsius, S.O.C medium and LB medium were warmed to room temperature, and 
Selective plates (100ug/ml ampicillin in LB Agar) were warmed in a 37 degree incubator 
for 30 minutes. 
One vial of Shot TOP10 (Invitrogen) chemically competent cells for each 
transformation was allowed to thaw on ice.  100 ng of DNA was added into a vial of One 
Shot cells and mixed gently. The vials were then incubated on ice for 30 minutes. The 
cells were heat-shocked for 30 seconds at 42 degree Celsius, and then put back on ice for 
2 minutes. 250 ul of pre-warned S.O.C medium was added to each vial.  The vial was 
capped tightly and shaken horizontally at 37 degree Celsius for 1 hour at 225 rpm in a 
shaking incubator.  200 ul from each transformation was spread a pre-warmed selective 




























Figure 2.6. In Vitro model of HPV16-Mediated Carcinogenesis. HKc cells are 
isolated from neonatal foreskins transfected with HPV16 plasmid DNA. 
HKc/HPV16 immortalized cells grew in the MCDB152-LB medium 
containing epidermal growth factor (EGF) and bovine pituitary extract (BPE) 
for proliferation. The derived HKc/GFI are selected in media containing high 
calcium (>0.3mM) and fetal bovine serum, giving rise to differentiation 
resistant cells (HKc/DR). HKc/DR when transfected with activated ras or 
HSV2 or SIX1 into nude mice, these HKc/DR cells developed into tumors. 
 Normal Human Keratinocytes (HKc) 
Transfected with 
HPV16 DNA 
Immortalized HKc (HKc/ HPV16 
Remove EGF and BPE 
Growth factor Independent (HKc/GFI)  
Serum or High 
Ca++ 
Differentiation Resistant HKc (HKc/DR)  
Transfect with 
activated ras or 
HSV2 Inject into 
nude mice  
TUMORS 




2.4 Making LB agar Plates 
  
250 mL of distilled water was measured and 25 grams of premix LB agar powder 
(VWR DF0445-17) was weighed and mixed well into solution. The total volume of the 
mix was brought to 500 mL with distilled water, and the solution was transferred to a 1L 
flask. This flask was put on a stirring hot plate and allowed to boil for 1 minute while 
stirring.  The solution was transferred to 1L Pyrex jar and labeled with autoclave tape. 
The 1L Pyrex jar was autoclaved at liquid setting for 20 minutes.  After agar had cooled 
down to about 55-degree Celsius, 25 ml of ampicillin (5 mg/ml) was added to the flask. 
Lastly, 20 ml of agar+amp was added to each 100 mm plates under the hood, and left to 
cool. The LB agar+amp plates were stored at +4 degree Celsius for later use.  
 
2.5 Cloning p53 shRNA 
 
 
P53 shRNA top strand 
GATCCCCTTGGCAGCCAFACTGCCTTTTCAAGAGAAAGGCAGTCTGGCTGCCAATTTT
TA 
P53 shRNA bottom strand 
AGCTTAAAAATTGGCAGCCAGACTGCCTTTTCTCTTGAAAAGGCAGTCTGGCTGCCA
AGGG 
Briefly, the general steps in utilizing a pSUPER.retro vector include annealing the 
forward and reverse strands for the shRNA (shown above). Second, linearize the 




annealed oligonucleotides into the vector; transform competent bacteria with the resulting 
ligation mix, selecting and amplifying colonies that contain the desired construct.  
Annealing the forward and reverse strands: The oligonucleotides were dissolved 
in nuclease free H2O to a concentration of 3 ug/mL. The annealing reaction was 
assembled by mixing 1 ul of each oligo (forward and reverse) with 48 ul of annealing of 
annealing buffer. This mixture was incubated at 90 degree Celsius for 4 min and at 70 
degree Celsius for 10 minutes. The annealed oligonucleotide was cooled slowly to 10 
degree Celsius and stored at -20 degree Celsius.  Second step of linearizing the vector 
(pSUPER.retro): 1 uL of the pSUPER.retro vector was linearized with BglII and HindIII 
restriction enzymes. The plasmid was first digested with HindIII overnight, followed by a 
second overnight digestion of BglII. The reaction was then heat inactivated, and the 
resulting DNA was separated by electrophoresis on a 1.1 % agarose gel. The band 
representing the pSuper plasmid with BglII/HindIII ends was purified as described below. 
 
 
2.6 Gel Purification of pSuper plasmid with BglII/HindIII end 
 
QIAquick Gel Extraction Kit was used to purify plasmid DNA. After digestion of 
plasmid DNA with HindIII and BglII, the resulting fragments were separated by 
electrophoresis on a 1.1% agarose gel, which was then stained with ethidium bromide. 
The DNA band was excised from the gel under long-wave UV light using a razor blade. 
The gel slice containing the DNA band of interest was cut into smaller pieces and placed 
into an Eppendorf tube. A volume of 400 ul of solution 1, equal to 3-fold the weight of 
the agarose sliced, was added to the agarose. The agarose was dissolved by incubation 




(provided in the kit) was added for collection of the plasmid DNA.  The contents were 
shaken for 15 minutes at room temperature. After centrifugation (1,000 x g for 10 
minutes) pellets were collected. Supernatant was discarded and re-suspension of pellet 
using NaI Followed. The sample was centrifuged once more, then the pellet was re-
suspended in 1 ml of new wash. This solution was transferred to a clean and sterile 
Eppendorf tube. This washing procedure was repeated multiple times. DNA was then 
eluted from the glass milk by re-suspension in distilled H2O. The suspension was 
centrifuged and the supernatant containing the DNA was transferred into a sterile 
Eppendorf tube.  
 
Ligation into pSUPER.retro vector: The cloning reaction was assembled by 
adding 2 uL of the annealed oligonucleotide to 1 uL of T4 DNA ligase buffer. Followed 
by addition of 1 uL of the digested pSUPER.retro vector, 5uL nuclease-free H2O and 1 
uL T4 DNA ligase. This mixture was incubated overnight at room temperature. After 
cloning and prior to transformation, plasmids were treated with BglII (1ul) and incubated 
for 30 minutes at 37 degrees Celsius to eliminate the vector that would have re-
circularized, as the BgLII site was destroyed in the recombinant plasmid, but not in the 
re-circularized vector. The plasmid was then transformed into bacteria (E. coli), followed 






Once the HKc/HPV16d-1 cells plated in 6-well plated reached 70-80% 




medium (KFSM) as recommended by the manufacturer. P53i-sh was also diluted in 
transfection medium. Lipofectamine 3000 and plasmid were then gently mixed (1:1 
ratio). The mixture was incubated for 5 minutes. 250 ul of this DNA-lipid complex was 
added to the cells and incubated for 6 hours at 37 degrees Celsius in a humidified 
atmosphere of 95%air/5%CO2.  Cells were then fed fresh KSFM, added to each well 
without removing the transfection mix. 
 
 
2.8 Puromycin selection 
 
 
After transfection (24hours post) , 2 mL of KSFM medium containing 3ug/mL of 
puromycin was added to each well containing transfected cells, which were then 
incubated for an additional 24 hours.  The medium was replaced with CM media and 
colonies were observed closely for several days until all non-transfected cells died, and 
transfected cells were ready to be collected for further analysis.  
 
2.9 UV light treatment 
 
 
Cells were allowed to grow until about 70-80% confluent at 37-degree Celsius. 
Cells were first washed using PBS and, while the cell culture dishes were left uncovered 
under the hood, the UV light was turned on for a short 30 seconds. CM medium was 
added back to the cells and dishes were put back into the incubator at 37 degree Celsius 
in a humidified atmosphere of 95%air/5%CO2 for various times (1h, 3h, 6h and 12h). 







2.10 Cell collection and Protein extraction  
 
 
CM media was aspirated when cells reached 80% confluence. After removal of 
media, 3 ml of 0.5 % of trypsin was added to the 100 mm dishes. The dishes were put 
back in the 37-degree Celsius incubator for 3 minutes or until cells were completely 
detached then 500 ul of FBS was added to the detached cell trypsin mixture, to inactivate 
the trypsin. The detached cells were then transferred to a 15 ml tube and centrifuged (in a 
clinical centrifuge) for minutes.  
Once the cell pellets was collected, 300ul of RIPA buffer (containing protease 
inhibitors) was added to each tube. The samples were then incubated on ice for 5 
minutes. The cell were re-suspended and lysed by vortex-ing.  After transfer of mixture to 
a 1.5ml tube, the samples were centrifuged at 8,000x g for 10 minutes. Supernatant with 
cell lysate was transferred to a new tube. Protein quantification was later performed to 
these samples.  
 
2.11 Bradford Assay 
 
The standard protocol was performed in In a 250 μl microplate assay. The 1x dye 
reagent was removed from 4°C storage and allowed to be warmed to ambient 
temperature. The 1x dye reagent was inverted a few times before use. 2-mg/ml gamma-
globulin standard was used. The following volumes were used 5ul of the standard in each 
well, 5ul of sample in each well and 190ul of 1x dye reagent in each well using 
disposable cuvette. Protein solutions were assayed in triplicate. For convenience, 6 




water and dye reagent. The samples were mixed using a microplate mixer. The plate was 
incubated at room temperature for 5 min. the spectrophotometer was set to 595 nm and 




 Sandwich ELISA Kit) 
 
The required microwell strips were allowed to reach room temperature. Cell 
lysates was diluted with Sample Diluent (supplied in each PathScan
®
 Sandwich ELISA 
Kit) to a set protein concentration. Addition of 100 µl diluted cell lysate to each well. 
The strips were then incubated overnight at 4°C. The strips were washed 4 times with 1X 
Wash Buffer using 200 µl (wash procedure) each time. After each wash, the strips were 
stroked on fresh towels in order to remove the residual solution in each well. 100 µl of 
reconstituted Detection Antibody (green color) was added to each well. The strips were 
incubated once more at 37°C for 1 hr. The “wash procedure” was repeated once more, 
followed by the Addition of 100 µl of reconstituted HRP-Linked secondary antibody to 
each well followed by incubation for 30 min at 37°C and “wash procedure”. After 
removal of reconstituted HRP-Linked secondary antibody, wells were again washed 
followed by the addition of 100 µl of TMB Substrate to each well. The strips were 
incubated for 10 min at 37°C or 30 min at 25°C, then 100 µl of STOP Solution was 
added to each well.  Absorbance was then measured at 450 mm. 
 
2.13 RNA Extraction  
 
 
RNA was extracted using RNeasy mini kit (Qiagen) with the manufacturer’s 




of Buffer RLT to the cell tube. The tubes were vortexed or pipetted for proper mixture. 
The lysates were homogenized accordingly by pipetting the lysate directly into a 
QIAshredder spin column placed in a 2 ml collection tube, and centrifuged for 2 min at 
full speed. 1 volume of 70% ethanol was added to the homogenized lysate, and mixed 
well by pipetting. The total volume of 700 μl of each sample was transferred from 
previous step, including any precipitate that may have formed. A volume of 700 μl Buffer 
RW1 was added to each RNeasy spin column. The flow-through is collected in the base. 
An additional volume of 500 μl Buffer RPE was added to each RNeasy spin column. 
Flow-through was again collected in the base. 500 μl Buffer RPE was added to each 
RNeasy spin column. The flow-through was once more collected in the base. Each 
column was placed in a 2 ml collection tube, centrifuged at full speed for 1 min. Each 
RNeasy spin column was placed in a new 1.5 ml collection tube were I Added 30–50 μl 
RNase-free water directly to each spin column membrane. Centrifuged for 1 min at 
_8000 x g (_10,000 rpm) to elute the RNA. The Collected RNA eluent was stored in -80 
degree Celsius freezer. 
 
 
2.14 cDNA Synthesis (iScript Kit) 
 
The following items were added to a small Eppendorf tube for a total volume of 20 
ul: Master mix recipe (20 ul total): 4 ul of 5x iScript reaction kit; 1 ul iScript reverse 
transcriptase; 4 ug/ul of RNA template and nuclease free water. The mixture was then 
vortexed, spun down and run cDNA was synthesized in a minicycler using iScript 




incubation scheme: 5 minutes at 25 degrees Celsius, 30 minutes at 42 degrees Celsius, 5 
minutes at 85 degrees Celsius, with an optional hold at 4 degree Celsius. Samples was 
diluted with 130 ul of RNF H2O and stored at -20 degree Celsius.  
 
2.15 Real time PCR 
 cDNA was used for this Real time PCR reaction. Using iQ SYBR green supermix 
(Bio-Rad), 25 ul of iQ SYBR green supermix was used per sample, with varied forward 
and reverse primer volume and varied RNF H2O for a total volume to 45 ul per reaction. 
cDNA samples were boiled for 2 minutes after  5 ul of cDNA was added to the respective 
wells of a 96-well Bio-Rad PCR plate along with 45 ul of master mix. Samples were run 
in triplicates. The plate was then sealed and centrifuged for 1 minute at 2000 rpm.  
The Bio-Rad iCycler used for this PCR reaction was at 8.5 min at 95 degree 
Celsius followed by 50 cycles of 95 degree Celsius for 30 seconds, 55 degree Celsius for 
30 seconds and 97 degree Celsius for 30 seconds. Completion of amplification with a 30 









3.1 Preliminary work  
  
 RNA interference approach was used in order to knockdown Tp53. The 
pSuper.p53 vector was used, this vector includes a 19-nucleotide sequence from the 
target mRNA (both sense and antisense orientation), separated by a short 9-nucleotide 
spacer sequence, shown in the figure below.  
Using the forward and reverse p53i-sh sequence, the following schematic 
transcript of the recombinant vector was made. This RNA product is predicted to fold 















Figure 3.7. Hairpin structure schematic  
Designed sequence:  
p53i-sh top strand:  
GATCCCCTTGGCAGCCAGACTGCCTTTTCAAGAGAAAGGCAGTCTGGCTGCCAATTTTT 
p53i-sh bottom strand:  
AGCTTAAAAATTGGCAGCCAGACTGCCTTTTCTCTTGAAAAGGCAGTCTGGCTGCCAAGGG 
These sequences were designed in such a way that they can form a hairpin loop 




Once our DNA plasmid was ready to use, I proceeded in cloning the p53i-sh RNA 










Figure 3.8 pSuper.retro puro map. PGK promoter: 2766-3164, Puro ORF: 3179-3778, 
H1 promoter: 2430-2650, Ampicillin resistance ORF: 6367-5501, 3’ delta LTR: 3848-
4201, 5’ LTR: 7293-513 (homologous to other MSCV LTR), Stuffer Sequence: 1447-
2423  






















Figure 3.9. Purification of digested plasmid DNA (pSuper.retro puro) DNA plasmid 
was successfully digested (linearization) with HindIII and BglII (restriction 
enzymes). The band representing the double-cut DNA plasmid was selectively cut 
out of the gel and extracted for cloning.  
Sample 1 Sample 2 Sample 3 
pSuper.retro puro plasmid 









The DNA plasmid pBabe puro H-rasV12 was ordered from Addgene. The DNA 








Figure 3.10. pBabe puro HrasV12 map. Mammalian Expression, Retroviral, Cloning 
method Restriction Enzyme: 5′ cloning site BamHI (not destroyed), 3′ cloning site 
EcoRI (not destroyed), 5′ sequencing primer pBABE-5. 3′ sequencing primer 
pBABE-3. Bacterial Resistance: Ampicillin, Growth Temperature: 37°C, Growth 







































Plasmid = 5811 bp 






Figure 3.11. DNA extraction Gel.  
Gel confirms successful presence and digestion of pBabe puro HrasV12 




3.2 Aim 1 
 
To determine whether mutated H-Ras (H-RasV12) expression results in changes 
in E7 and Rb expression levels in different HKc/HPV16 and HKc/DR lines different assay 
was performed to measure Rb and E7 protein levels.  
HKc/HPV16d-1 cells were transfected with mutated H-Ras, then RNA and 
protein were collected for RT/PCR for E7 and ELISA for Rb, assays using 
HKc/HPV16d-1 non-transfected as controls. We observed a significant decrease in E7 
mRNA expression in the H-RasV12 transfected HKc/HPV16d-1 cells as compared to the 
non-transfected cells lines (Figure 12). As expected, this decrease in E7 expression was 
accompanied by a marked increase in Rb protein levels detected by ELISA in cell lysates 
from H-rasV12-expressing HKc/HPV16d-1, compared to their controls (Figure 13), 





























D1++ not transfected D1++ HRas
RTq-PCR E7 levels in HKc/HPV16 transfected cells  
Figure 3.12: RT/q-PCR results for E7 levels HKc16/D1++ HRas transfected and non-




















Figure 3.13. Rb levels in HKc/HPV16d-1 (D1++) cells transfected with H-Ras and 

















3.3 Aim 2 
To determine whether p53 can be knock-down by the means of an shRNA in 
Human Keratinocyte lines transformed with HPV16 (HKc/HPV16) and HKc/DR lines. 
3.3.1UV treatment results  
First, in order for the cells to produce sufficient amount of p53 protein, normal 
human keratinocytes (HKc) and HKc/HPV16 were stressed using UV light in order to 
induce p53 protein production. The cells were given some time to recover with fresh CM 
medium after the UV treatment (1, 3, 6 and 12 hours). p53 protein levels were first 
measured via ELISA in normal (HKc) as a control. The graph below (figure 14) shows 
the result of p53 ELISA after UV treatment in HKc. In UV treated cells, we can make 
better comparisons in p53 protein levels between the following groups: HKc non-treated, 
HKc 1 hour after treatment and HKc 12 hours after treatment. HKc/HPV16 cell lines p53 
ELISA after UV treatment graphs are also shown below (figure 15 and 16). HKc/HPV16 
non-transfected cell lines, early passage number (figure 15), did not respond to UV 
treatment until 12 hours, where we noticed a slight increase in p53 proteins levels. 
However, later passage HKc/HPV16 non-transfected cell lines (Figure 16) did not have a 












































 Figure 3.14. p53 ELISA results in normal HKc. P53 protein levels was shown to 
significantly increase after 1 and 12 hour after UV treatment as compared the 









































HKC/HPV16 D1 NON-TRANSFECTED, p53 ELISA  
Figure 3.15. p53 ELISA results in HKc/HPV16 non-transfected UV 
treated cells. (Passage number: 25). A significant decrease in p53 protein 
levels in HKc/HPV16 (D1++) transformed cell lines was noticed as 
compared to a normal human keratinocytes (HKc). After UV treatment, 
we do not notice an increase in p53 protein levels (at 1h and 3h after UV) 
































HKc/HPV16 NON-TRANSFECTED, p53 ELISA  
Figure 3.16. 53 ELISA results in HKc/HPV16 non-transfected UV treated 
cells. (Passage number: 35) Once again we notice a significant decrease in 
p53 protein as compared to normal Human keratinocytes (HKc/normal). 
However p53 protein levels stayed the same after UV treatment (1h, 3h, 6h 




3.3.2 Human Keratinocyte lines transformed with HPV16 (HKc/HPV16) and 
HKc/DR lines 
I wanted to determine whether p53 can be knock-down by the means of an 
shRNA in Human Keratinocyte lines transformed with HPV16 (HKc/HPV16) and 
HKc/DR lines. Therefore, I performed a p53 ELISA in our HKc/HPV16 transfected with 
p53i-sh cell line (and their respective controls), additionally we treated them with UV to 
induce p53 production. Figure 15 shows the results of a p53 ELISA comparing p53 levels 
in HKc/HPV16d-1 (D1++) to normal HKc and to D1++ transfected with p53shRNA. As 
compared to control normal HKc, the HKc/HPV16d-1 cell line expresses significantly 
lower level of p53 protein. In HKc/HPV16d-1 transfected with p53i-sh (D1++ non-
transfected, non UV) we observe even lower p53 proteins levels. However after UV 
treatment, the HKc/HPV16d-1 cell lines transfected with p53i-sh still show a surprising 
ability to increase expression of p53, which returns to almost the same level of protein 
observed in our control (HKc), but does not reach the expression levels triggered by UV 

















































HKc/HPV16 D1,  P53 Elisa 
Figure 3.17. Tp53 ELISA results in the HKc/HPV16d-1 cell line (D1++).  The bar 
graph is listed as follows (left to right) HKc (normal), HKc/HPV16 D1 (non-
transfected and non-UV treated), HKc/HPV16 D1 transfected with p53i-sh (non-UV 
treated), HKc/HPV16 D1 transfected with p53i-sh (1hour after UV treatment), 
HKc/HPV16 D1 transfected with p53i-sh (3hour after UV treatment), HKc/HPV16 
D1 transfected with p53i-sh (6hour after UV treatment), HKc/HPV16 D1 transfected 






Looking at the morphology of HKc/HPV16 cells transfected with p53i-sh after 
UV treatment, we notice that the cells are very responsive to UV treatment, as early as 1 
hour after UV.  
 
 
   
 
   
 




Figure 3.18 UV treated HKc/HPV16 
cell morphology. The HKc cell line 
with no UV treatment has a more 
elongated shape and adhere better to 
cell culture plate as compared to UV 
treated cell line which were less 
adherent to the cell culture plate and 
cell shape were more rounded. In 
addition, it was noticed that the more 
prolonged the recovery time, the higher 
the percentage of cell death.  
No UV 1h after UV 
3h after UV 6h after UV 




            Differentiation resistant (HKc/DR) cells lines were transfected with p53i-sh and 





































P53 Elisa for D1DR cells transfected 
with p53i-sh 
D1DR-p53i sh UV treated  
Figure 3.19. HKc/DR Similar to our HKc/HPV16 p53i-sh transfected cells line. 
We also notice a significant decrease in p53i protein levels in our differentiation 
resistant transfected cell lines as compared to our control (HKc/Normal). When 
UV treated, the p53 protein levels in those cell did increase, however we notice a 
rather an unsettle increase and decrease of p53 proteins levels in those cells after 




Looking at the morphology of HKc/DR cells transfected with p53i-sh after UV 
treatment, we notice that the cells are more resistant to UV treatment. Morphological 
changes due to UV treatment is not noticed until 6 and 12 hour after UV. 
    






No UV 1h after UV 
6h after UV 
12h after UV 
3h after UV 
Figure 3.20 UV treated HKc/DR cell 
morphology. HKc/DR p53i-sh 
Morphological changes due to UV 
appeared after 6 hour where the cells 
started to detach from the cell 
culture plate. However only 12-hour 
after UV, significant cell death 





Furthermore, an ELISA assay was done in order to detect a difference in p53 
protein levels in the HKc/HPV16 D1 transfected with mutated HRAs using the ELISA 
assay (Figure 22). Surprisingly, HKc/HPV16d-1 cells transfected with H-RasV12 showed 
lower levels of p53, as compared to their non-transfected controls. As expected, 
HKc/HPV16 D1 non-transfected had much lower p53 protein expression as compared to 






























p53 ELISA in HKc/HPV16d-1 cells 
transfected with HRas  









We noticed in the data shown above that p53 levels were at least ten-fold higher 
in normal HKc than in HKc/HPV16d-1 not exposed to UV. This difference is to be 
attributed to the fact that in HKc/HPV16, E6 promotes p53 degradation; hence the 
steady-state levels of p53 are much lower. Transfection with the p53shRNA plasmid 
decreases steady-state p53 levels even more (D1++angp53i Transfected). When treated 
with UV, the p53i-transfected HKc/HPV16 cells show a further decrease in p53 levels 
after one hour, and a delayed increase at 6 h. However, at 12 hours after UV treatment, 
the levels of p53 in D1++angp53i Transfected cells are still lower than those in untreated 
normal HKc. As shown in figure 11, HPV16 E7 mRNA levels decreased by about 2/3 in 
HKc/HPV16d-1 transfected with H-RasV12. This may indicate that H-RasV12 is 
partially “replacing” E7 function. To confirm that E7 expression was indeed decreased in 
these cells, we performed an ELISA for Rb. As expected, the Rb ELISA shows a marked 
increase in Rb protein levels in the HKc/HPV16d-1 cells transfected with H-RasV12. 
This indicates that E7 function is at least partially lost in these cells, and Rb is no longer 
being degraded or at least not to the same extent as in non-transfected HKc/HPV16d-1. 
As I previously mentioned, HARasV12-transfected HKc/HPV16 express lower 
levels of HPV16 E7 (figure 12), and E7 function appears to be decreased as well, because 
Rb protein levels rise (figure 13). This finding supports the notion that E7 function may 




proliferation. HKc/HPV16, and HKc/HPV16 expressing an shRNA against p53, exhibit 
some residual ability to respond to UV treatment with an induction of p53 (figure 18). 
Accordingly, UV treatment produces visible damage in these cells. HKc/DR appear to be 
more resistant than HKc/HPV16 to UV treatment, exhibiting only minor (if at all) 
increases in p53 levels. Thus, morphological evidence of cells death in UV treated 
HKc/DR is observed only 12h after treatment and not earlier (figure 20). These are 
interesting observations that warrant full characterization of the UV responses of HPV-
transformed cells at early and late stages of progression. P53 levels decrease slightly in 
HKc/HPV16 transfected with HRasV12(figure 21): this could be due to the decrease of 
E7 levels and activity, as E7 is known to stabilize p53. More work is needed to determine 
the levels of E6 and E7 in p53shRNA-expressing HKc/HPV16 and HKc/DR, to 
conclusively provide proof of principle for our hypothesis 
 
Future Work 
The results shown above are encouraging. However, we need to demonstrate 
positively that H-Ras is expressed in the transfected cells, and also investigate how H-Ras 
cells grow: we have observed slower growth in H-RasV12-transfected cells than in their 
parental cell line, but we need to actually measure their growth rate. We presume that the 
decrease in E7 mRNA expression would be accompanied by a decrease in E6, as E6 and 
E7 messages derive from the same polycistronic mRNA, and in order to produce E7 cells 
must splice out most of E6.  With less E6, there is more p53 to go around, and cells are 




presume that this may be the mechanism that slows down growth in H-RasV12-
transfected cells, but we need to demonstrate that this is (or is not) the case. 
Additionally, we should assess the effects of the combined expression of p53 
shRNA and H-RasV12 on E6/E7 expression in HKc/HPV16 and HKc/DR lines by co-
transfection of p53 and H-Ras12in HKc/HPV16 cells lines. Using this approach will help 
us to assess if HKc/HPV16 and HKc/DR lines can become more independent on E6/E7 
activities for proliferation. Additional efforts should be dedicated to exploring the 
mechanisms by which HRas signaling leads to decreased expression of E7 in 
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